|
1
|
Boussen H, Bouzaiene H, Ben Hassouna J,
Gamoudi A, Benna F and Rahal K: Inflammatory breast cancer in
Tunisia: Reassessment of incidence and clinicopathological
features. Semin Oncol. 35:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Labidi SI, Mrad K, Mezlini A, Ouarda MA,
Combes JD, Ben Abdallah M, Ben Romdhane K, Viens P and Ben Ayed F:
Inflammatory breast cancer in Tunisia in the era of multimodality
therapy. Ann Oncol. 19:473–480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dawood S, Merajver SD, Viens P, Vermeulen
PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A,
Krishnamurthy S, et al: International expert panel on inflammatory
breast cancer: Consensus statement for standardized diagnosis and
treatment. Ann Oncol. 22:515–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fouad TM, Barrera AMG, Reuben JM, Lucci A,
Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, et
al: Inflammatory breast cancer: A proposed conceptual shift in the
UICC-AJCC TNM staging system. Lancet Oncol. 18:e228–e232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W,
Wei W and Sun S: Outcomes of patients with inflammatory breast
cancer by hormone receptor- and HER2-defined molecular subtypes: A
population-based study from the SEER program. Oncotarget.
8:49370–49379. 2017.PubMed/NCBI
|
|
6
|
Mirecka J, Korabiowska M and Schauer A:
Correlation between the occurrence of Ki-67 antigen and clinical
parameters in human breast carcinoma. Folia Histochem Cytobiol.
31:83–86. 1993.PubMed/NCBI
|
|
7
|
Boussen H, Bouzaiene H, Ben Hassouna J,
Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal
K and Levine PH: Inflammatory breast cancer in Tunisia:
Epidemiological and clinical trends. Cancer. 116 Suppl
11:2730–2735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mourali N, Muenz LR, Tabbane F, Belhassen
S, Bahi J and Levine PH: Epidemiologic features of rapidly
progressing breast cancer in Tunisia. Cancer. 46:2741–2746. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maalej M, Hentati D, Messai T, Kochbati L,
El May A, Mrad K, Romdhane KB, Ben Abdallah M and Zouari B: Breast
cancer in Tunisia in 2004: A comparative clinical and
epidemiological study. Bull Cancer. 95:E5–E9. 2008.PubMed/NCBI
|
|
10
|
Chaher N, Arias-Pulido H, Terki N, Qualls
C, Bouzid K, Verschraegen C, Wallace AM and Royce M: Molecular and
epidemiological characteristics of inflammatory breast cancer in
Algerian patients. Breast Cancer Res Treat. 131:437–444. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mejri N, Boussen H, Labidi S, Bouzaiene H,
Afrit M, Benna F and Rahal K: Inflammatory breast cancer in Tunisia
from 2005 to 2010: Epidemiologic and anatomoclinical transitions
from published data. Asian Pac J Cancer Prev. 16:1277–1280. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirko KA, Soliman AS, Banerjee M,
Ruterbusch J, Harford JB, Chamberlain RM, Graff JJ, Merajver SD and
Schwartz K: Characterizing inflammatory breast cancer among Arab
Americans in the California, Detroit and New Jersey Surveillance,
Epidemiology and End Results (SEER) registries (1988–2008).
Springerplus. 2:32013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldner B, Behrendt CE, Schoellhammer HF,
Lee B and Chen SL: Incidence of inflammatory breast cancer in
women, 1992–2009, United States. Ann Surg Oncol. 21:1267–1270.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Levine PH and Veneroso C: The epidemiology
of inflammatory breast cancer. Semin Oncol. 35:11–16. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Charafe-Jauffret E, Mrad K, Intidhar
Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier
C, Esterni B, Birnbaum D, Ben Ayed F and Xerri L: Inflammatory
breast cancers in Tunisia and France show similar immunophenotypes.
Breast. 16:352–358. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Veneroso C, Siegel R and Levine PH: Early
age at first childbirth associated with advanced tumor grade in
breast cancer. Cancer Detect Prev. 32:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schairer C, Li Y, Frawley P, Graubard BI,
Wellman RD, Buist DS, Kerlikowske K, Onega TL, Anderson WF and
Miglioretti DL: Risk factors for inflammatory breast cancer and
other invasive breast cancers. J Natl Cancer Inst. 105:1373–1384.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Obr AE and Edwards DP: The biology of
progesterone receptor in the normal mammary gland and in breast
cancer. Mol Cell Endocrinol. 357:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zwart W, Theodorou V and Carroll JS:
Estrogen receptor-positive breast cancer: A multidisciplinary
challenge. Wiley Interdiscip Rev Syst Biol Med. 3:216–230. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: A systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Viale G, Giobbie-Hurder A, Regan MM,
Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G,
Braye SG, Ohlschlegel C, et al: Prognostic and predictive value of
centrally reviewed Ki-67 labeling index in postmenopausal women
with endocrine-responsive breast cancer: Results from Breast
International Group Trial 1–98 comparing adjuvant tamoxifen with
letrozole. J Clin Oncol. 26:5569–5575. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masuda H, Brewer TM, Liu DD, Iwamoto T,
Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M,
Fouad TM, et al: Long-term treatment efficacy in primary
inflammatory breast cancer by hormonal receptor- and HER2-defined
subtypes. Ann Oncol. 25:384–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cristofanilli M, Gonzalez-Angulo AM,
Buzdar AU, Kau S-W, Frye DK and Hortobagyi GN: Paclitaxel improves
the prognosis in estrogen receptor negative inflammatory breast
cancer: The M. D. Anderson Cancer Center experience. Clin Breast
Cancer. 4:415–419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cristofanilli M, Buzdar AU, Sneige N,
Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero
V, et al: Paclitaxel in the multimodality treatment for
inflammatory breast carcinoma. Cancer. 92:1775–1782. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jatoi I, Hilsenbeck SG, Clark GM and
Osborne CK: Significance of axillary lymph node metastasis in
primary breast cancer. J Clin Oncol. 17:2334–2340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pisansky TM, Schaid DJ, Loprinzi CL,
Donohue JH, Schray MF and Schomberg PJ: Inflammatory breast cancer:
Integration of irradiation, surgery and chemotherapy. Am J Clin
Oncol. 15:376–387. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cristofanilli M, Valero V, Buzdar AU, Kau
SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT,
Buchholz TA, et al: Inflammatory breast cancer (IBC) and patterns
of recurrence: Understanding the biology of a unique disease.
Cancer. 110:1436–1444. 2007. View Article : Google Scholar : PubMed/NCBI
|
